Summary

Although disease-modifying therapies work best when given early in MS, the decision to proactively treat patients with radiologically isolated syndrome (RIS) is countered by the increasing risks associated with disease-modifying therapies as well as the uncertain prognostic outcome of RIS [Spain R, Bourdette D. Curr Neurol Neurosci Rep 2011].